Could cause temporary or reversible harm; serious harm is unlikely.
Failed Impurities/Degradation Specifications - OOS impurities result observed during long term stability testing at product expiry (24 months) were above specs for these impurities: Dexamethasone Sodium Phosphate EP impurity G (Impurity RU 49336) and dexamethasone formate.
| Brand name | DEXAMETHASONE SODIUM PHOSPHATE |
| Generic name | DEXAMETHASONE SODIUM PHOSPHATE |
| Active ingredient(s) | DEXAMETHASONE SODIUM PHOSPHATE |
| Distributed by / for | Somerset Therapeutics, LLC., Somerset, NJ 08873 |
| Full product label | Dexamethasone Sodium Phosphate Injection, USP, 100 mg/ 10 mL, (10 mg/mL), 10x10 mL Multiple Dose Vials, Rx only, Manufactured for: Somerset Therapeutics, LLC., Somerset, NJ 08873, NDC carton: 70069-025-10; NDC vial: 70069-025-01 |
| Recalling firm | SOMERSET THERAPEUTICS LLC |
| Distribution | Nationwide in the USA |
| Quantity | 62190 vials |
| Recall initiated | 2026-02-04 |
| Report date | 2026-03-25 |
| Recall completed | — |
| Recall number | D-0398-2026 |
| Classification | Class II |
| FDA status | Ongoing |
| Origin on file | Somerset NJ United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗